文献速递慢性肾脏病肾血管病与高血压

慢性肾脏病患者单核细胞钙敏感受体表达降低与血管钙化抑制能力受损相关

Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification.
PubMed 文献 · Kidney Int · 2021-02-27

横断面研究显示,CKD 4-5 期患者外周血单个核细胞总 CaSR 及单核细胞表面 CaSR 表达分别降低 43% 和 34%,且与单核细胞体外抑制血管钙化能力下降相关。拟钙剂 NPSR568 预处理可改善 CKD 患者单核细胞减少颈动脉钙化的能力,细胞表面 CaSR 表达越少,改善越明显。

要点

  • CKD 4-5 期患者单核细胞总 CaSR 和表面 CaSR 表达分别降低 43% 和 34%。
  • 单核细胞 CaSR 表达降低与体外抑制血管钙化能力下降相关。
  • 拟钙剂 NPSR568 可改善 CKD 患者单核细胞减少血管钙化的能力。

核心结论

  • CKD 患者单核细胞 CaSR 表达降低,可能促进血管钙化,靶向该改变或监测单核细胞 CaSR 表达有望成为 CKD 相关动脉钙化的治疗策略。

研究设计与样本

  • 横断面研究检测不同分期 CKD 患者与健康志愿者单核细胞总 CaSR 及表面 CaSR 表达。
  • 体外实验用尿毒血清处理 U937 和 THP-1 细胞系,并用人外周血单个核细胞或单核细胞系观察对大鼠颈动脉血管钙沉积的影响。

主要发现

  • CKD 4-5 期患者外周血单个核细胞总 CaSR 表达降低 43%,单核细胞表面 CaSR 表达降低 34%。
  • 单核细胞 CaSR 表达降低与其体外抑制血管钙化能力下降相关。
  • NPSR568 预处理 CKD 患者外周血单个核细胞可显著提高其减少颈动脉钙化的能力。
  • 表达细胞表面 CaSR 的外周血单个核细胞越少,拟钙剂治疗增强减少颈动脉钙含量的效果越明显。

临床怎么用

  • 单核细胞 CaSR 表达可能作为 CKD 相关血管钙化的可及生物标志物。
  • 拟钙剂改善单核细胞抗钙化功能的作用值得进一步临床验证。

局限性

  • 研究为横断面设计,无法确立因果关系。
  • 体外实验使用细胞系和大鼠颈动脉模型,结果外推至人体需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In chronic kidney disease (CKD), calcium-sensing receptor (CaSR) expression and function have been extensively studied in parathyroid tissue and vascular tissues. To examine whether similar changes occurred in other tissues, we measured total and surface CaSR expression in monocytes of patients with various stages of CKD and healthy volunteers respectively in cross-sectional studies. We further explored in vitro the impact of uremic serum on CaSR expression in monocytes (U937 and THP-1 cell lines), and whether human peripheral blood mononuclear cells or U937 and THP-1 monocytes might modify vascular calcium deposition in rat carotid arteries in vitro. CKD was associated with a decrease in peripheral blood mononuclear cell CaSR expression both in total and at the monocyte surface alone (43% and 34%, respectively in CKD stages 4-5). This decrease was associated with a reduction in the ability of monocytes to inhibit vascular calcification in vitro. Pretreatment with the calcimimetic NPSR568 of peripheral blood mononuclear cells isolated from patients with CKD significantly improved monocyte capacity to reduce carotid calcification in vitro. The fewer peripheral blood mononuclear cells expressing cell surface CaSR, the more calcimimetic treatment enhanced the decrease of carotid calcium content. Thus, we demonstrate that monocyte CaSR expression is decreased in patients with CKD and provide in vitro evidence for a potential role of this decrease in the promotion of vascular calcification. Hence, targeting this alteration or following monocyte CaSR expression as an accessible marker might represent a promising therapeutic strategy in CKD-associated arterial calcification.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Mary A, Objois T, Brazier M, et al. Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification. Kidney Int. 2021. PMID: 33647324. doi:10.1016/j.kint.2021.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。